Need Help With This Product?
Our specialists are here to help you find the best product for your application.
iCell Cardiomyocytes DCM LMNA L35P, 01016 and Isogenic Control
Product Overview
Lamin A/C LMNA mutations are a common cause of dilated cardiomyopathy (DCM). Clinically, DCM is characterized by ventricular dilation concurrent with reduced systolic function and arrhythmias. A missense mutation in the gene encoding the lamin A/C protein (LMNA) results in a change of amino acid 35 from leucine-to-proline (L35P).
To enable researchers to study functional cardiac consequences, somatic cells from an individual carrying the LMNA L35P mutation were reprogrammed to generate iCell® Cardiomyocytes DCM (L35P), 01016. In addition, an isogenic control, iCell Cardiomyocytes Corrected DCM (L35P), was generated using genome engineering strategies to correct the mutation. iCell Cardiomyocytes (L35P) display classic hallmarks of dilated cardiomyopathy including abnormal contractile properties (i.e. reduced contraction amplitude).
Best-in-Class Biology
iCell Cardiomyocytes (L35P) and its isogenic control (L35P Corrected) exhibit the relevant biology and functionality to advance research and preclinical studies for devastating congenital muscular dystrophies, laminopathies, and cardiomyopathies.
- Fully differentiated, >90% pure cardiomyocytes
- Expression of relevant cardiac markers (e.g. cTNT, ACTN2)
- Isogenic control available
Components:
Our regular business hours are 9:00am to 5:00pm Central Time (USA)
Need Help With This Product?
Our specialists are here to help you find the best product for your application.
Our regular business hours are 9:00am to 5:00pm Central Time (USA)
Technical Docs
PROTOCOLS
Application Notes
Assaying Caspase Activity & Apoptosis
Application Notes
Assaying Cell Viability
Application Notes
Assaying Cytotoxicity
Application Notes
Assaying Mitochondrial Membrane Potential
Application Protocols
Dissociating Cardiomyocytes by Enzymatic Treatment
Application Protocols
Extracting Total RNA
Application Protocols
Immunofluorescent Labeling of iCell Cardiomyocytes
Application Protocols
Measuring Cardiac Activity: Impedance Detection with xCELLigence RTCA Cardio System
Application Protocols
Measuring Cardiac Activity: Intracellular Calcium Flux Detection on the FLIPR Tetra System
Application Protocols
Measuring Cardiac Electrical Activity: Field Potential Detection with Axion Maestro Multielectrode Array
Application Protocols
Measuring Cardiac Electrical Activity: Field Potential Detection with Multielectrode Array
Application Protocols
Measuring Cardiac Electrical Activity: Manual Perforated Patch Clamp
Application Protocols
Modeling Cardiac Hypertrophy: Endothelin-1 Induction with ELISA Analysis
Application Protocols
Modeling Cardiac Hypertrophy: Endothelin-1 Induction with Flow Cytometry Analysis
Application Protocols
Modeling Cardiac Hypertrophy: Endothelin-1 Induction with High Content Analysis
Application Protocols
Modeling Cardiac Hypertrophy: Endothelin-1 Induction with qRT-PCR Analysis
Application Protocols
Modeling Cardiac Ischemia: Hypoxia Induction for Cardioprotection Screening
Application Protocols
Using Liposome-mediated Transfection for Gene Delivery - iCell Cardiomyocytes
Application Protocols
Using Transfection for siRNA Delivery
USER DOCS
User's Guides
iCell Cardiomyocytes
Datasheet
iCell Cardiomyocytes
Biosafety Document
iCell Cardiomyocytes Corrected DCM (L35P) Biosafety Document
Biosafety Document
iCell Cardiomyocytes DCM (L35P) Biosafety Document
Safety Data Sheet
iCell Cell-Based Products Safety Data Sheet - Asia
Safety Data Sheet
iCell Cell-Based Products Safety Data Sheet
Safety Data Sheet
iCell Cardiomyocytes Maintenance Medium, iCell Cardiomyocytes Plating Medium Safety Data Sheet - Germany
Performance Data
Comparison of MyCell Cardiomyocytes (L35P) and Isogenic Control
Representative phase contrast images (20X) of isogenic control and MyCell Cardiomyocytes (L35P) reveal comparable structure when plated at 20,000 cells per well in 96-well format. (DIV14)
Figure 1: Morphology Assessment
Figure 2: Contractility Measurements (Impedance)
Contractility Measurements (Impedance)
Contractility was monitored by measuring impedance over time. MyCell Cardiomyocytes (L35P) display reduced contraction amplitude relative to isogenic control. (DIV 14)
Calcium Handling Assessment
Representative calcium transients reveal that MyCell Cardiomyocytes (L35P) display increase beat rate relative to isogenic control. (DIV 14)
Figure 3: Calcium Handling Assessment
Publications
Electronic Cigarette Extract Induced Toxic Effect in iPS-derived Cardiomyocytes Hesham Basma, Swetha Tatineni, Kajari Dhar, Fang Qiu, Stephen Rennard, Brian D. Lowes (2020) BMC Cardiovasc Disord. 20: 357. (2020)
Inhibition of RNA Helicase Activity Prevents Coxsackievirus B3-Induced Myocarditis in Human iPS Cardiomyocytes Yun SH, Shin HH, Ju ES, Lee YJ, Lim BK & Jeon ES (2020) Int. J. Mol. Sci. 21: 3041. (2020)
Selective Induction of Human Autonomic Neurons Enables Precise Control of Cardiomyocyte Beating Takayama Y, Kushige H, Akagi Y, Suzuki Y, Kumagai Y & Kida YS (2020) Scientific Reports 10: 9464 (2020)
Detection of Drug-Induced Torsades de Pointes Arrhythmia Mechanisms Using hiPSC-CM Syncytial Monolayers in a High-Throughput Screening Voltage Sensitive Dye Assay da Rocha AM, Creech J, Thonn E, Mironov S, Herron TJ (2020) Toxicol Sci. 173(2):402-415 (2020)
Multiplexed Optical Sensors in Arrayed Islands of Cells for Multimodal Recordings of Cellular Physiology Christopher A. Werley, Stefano Boccardo, Alessandra Rigamonti, Emil M. Hansson & Adam E. Cohen (2020) Nature Comm. 11: 3881. (2020)
Assessing SSRIs' Effects on Fetal Cardiomyocytes Utilizing Placenta-Fetus Model Arumugasaamy N, Hurley-Novatny A, Lembong J, Kim PCW, Fisher JP. (2019) Acta Biomater. 99:258-268. (2019)
TGF-β Induces a Heart Failure Phenotype via Fibroblasts Exosome Signaling Basma H, Johanson AN, Dhar K, Anderson D, Qiu F, Rennard S, Lowes BD. (2019) Heliyon, 5:10, e02633. (2019)
Resolving the Reversed Rate Effect of Calcium Channel Blockers on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes and the Impact on in vitro Cardiac Safety Evaluation. Zeng H, Wang J, Clouse H, Lagrutta A, and Sannajust F. Toxicol Sci. (2019) 167(2):573-580. (2019)
Inhibitory Effects of Class 1 Antiarrhythmic Agents on Na+ and Ca2+ Currents of Human iPS Cell-derived Cardiomyocytes Yonemizu S, Masuda K, Kurata Y, Notsu T, Higashi Y, Fukumura K, Li P, Ninomiya H, Miake J, Tsuneto M, Shirayoshi Y, Hisatomea I (2019) Regen Ther 10: 104–111. (2019)
Human Cardiac Organoids for the Modeling of Myocardial Infarction and Drug Cardiotoxicity Richards DJ, Li Y, Kerr CM, Yao J, Beeson GC, Coyle RC, Chen X, Jia J, Damon B, Wilson R, Starr Hazard E, Hardiman G, Menick DR, Beeson CC, Yao H, Ye T, Mei Y (2020) Nat Biomed Eng. 4(4):446-462. (2020)